CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

TALPHERA, INC.

TLPH
$61MMicro Cap

Next catalyst

NDA FilingJanuary 2027

NDA Filing - Niyad

Get an email about TLPH's next catalysts

Track TALPHERA (TLPH) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 1 more upcoming event in our data (regulatory event).See the timeline

Catalyst Timeline

2 upcoming, 1 past

Regulatory

Regulatory Decision - Niyad

Dec 31, 2026

Talphera outlined a plan to seek FDA agreement to end enrollment in the NEPHRO trial by Dec. 31, 2026. The company also raised its peak U.S. sales view for Niyad to over $200M.

Source
NDA FilingNext

NDA Filing - Niyad

January 2027~

Talphera announced plans to file Niyad for PMA (Premarket Approval) in 2026 with anticipated approval in 2027, while NEPHRO trial enrollment has surpassed 50%.

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical Preparations🇺🇸North AmericaSAN MATEO

Frequently asked questions

What is in TALPHERA, INC.'s drug pipeline?→

CatalystAlert tracks 8 drug candidates in TALPHERA, INC.'s (TLPH) pipeline across Phase 3, Phase 2. Its lead program is morphine IV PCA (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is TALPHERA, INC.'s next FDA catalyst?→

TALPHERA, INC.'s (TLPH) next tracked catalyst is an NDA filing expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track TLPH biotech catalysts?→

Add TLPH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TALPHERA, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply